Altimmune, Inc. (NASDAQ:ALT) Q3 2020 Earnings Conference Call November 10, 2020 8:30 AM ET Company Participants Stacey Jurchison - Investor Relations Vipin Garg - Chief Executive Officer Scot Roberts - Chief Scientific Officer Scott Harris - Chief Medical Officer Will Brown - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Mayank Mamtani - B. Riley FBR Jon Wolleben - JMP Securities Operator Good morning and welcome to the Altimmune, Inc. Third Quarter 2020 Earnings Confe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32587 ALTIMMUNE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-2726770 (State or Other Jurisdictio ...

Altimmune, Inc. (NASDAQ:ALT) Q2 2020 Earnings Conference Call August 12, 2020 8:30 AM ET Company Participants Monique Kosse - IR, LifeSci Advisors Vipin Garg - Chief Executive Officer Scot Roberts - Chief Scientific Officer Scott Harris - Chief Medical Officer Will Brown - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Jonathan Wolleben - JMP Securities Operator Greetings and welcome to the Altimmune Inc. Second Quarter 2020 Earnings Call. At this time, all participants ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

Altimmune, Inc. (NASDAQ:ALT) Q1 2020 Earnings Conference Call May 14, 2020 8:30 AM ET Company Participants Monique Kosse - IR, LifeSci Advisors Vipin Garg - CEO Will Brown - CFO Scot Roberts - Chief Scientific Officer Scott Harris - Chief Medical Officer Conference Call Participants Yasmeen Rahimi - ROTH Capital Partners Jim Molloy - Alliance Global Partners Operator Thank you for standing by. This is the conference operator. Welcome to the Altimmune Incorporated First Quarter 2020 Earnings Conference Call. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share ALT The NASDAQ Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ALTIMMUNE, INC. (Exact name of registrant as specified in its charter) FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 ☐ Transition Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-32587 Delaware 20-2726770 (State or other jurisdiction of incorporatio ...